-
17590-1A selective CaMKII inhibitor (IC<sub>50</sub> = 40 nM) that was designed based on the sequence around the autophosphorylation site (Thr286/Thr287) in the autoinhibitory domain of the protein kinase.
-
17590-10
Thomas Scientific
Autocamtide-2-related Inhibitory Peptide-10 mg
Price: $1,208.79List Price: $1,343.10A selective CaMKII inhibitor (IC<sub>50</sub> = 40 nM) that was designed based on the sequence around the autophosphorylation site (Thr286/Thr287) in the autoinhibitory domain of the protein kinase. -
17590-5A selective CaMKII inhibitor (IC<sub>50</sub> = 40 nM) that was designed based on the sequence around the autophosphorylation site (Thr286/Thr287) in the autoinhibitory domain of the protein kinase.
-
11INSC0106Specially designed for Southern and Northern applications. MP Bio cassettes can be used at temperatures as low as -80C. The high quality materials used in manufacturing these cassettes insure outstanding durability.
-
9000753-1A fluorescently-tagged probe consisting of C-10 ceramide with an AV group attached to the end of the acyl chain.
-
9000753-10A fluorescently-tagged probe consisting of C-10 ceramide with an AV group attached to the end of the acyl chain.
-
9000753-25A fluorescently-tagged probe consisting of C-10 ceramide with an AV group attached to the end of the acyl chain.
-
9000753-5A fluorescently-tagged probe consisting of C-10 ceramide with an AV group attached to the end of the acyl chain.
-
16711-1A potent, orally bioavailable inhibitor of &gamma-secretase that more potently inhibits the cleavage of APP to A&beta40 than signaling through Notch (IC<sub>50</sub>s = 0.30 and 58 nM, respectively) shows good pharmacokinetics in rats, dogs, and
-
16711-10A potent, orally bioavailable inhibitor of &gamma-secretase that more potently inhibits the cleavage of APP to A&beta40 than signaling through Notch (IC<sub>50</sub>s = 0.30 and 58 nM, respectively) shows good pharmacokinetics in rats, dogs, and
-
16711-5A potent, orally bioavailable inhibitor of &gamma-secretase that more potently inhibits the cleavage of APP to A&beta40 than signaling through Notch (IC<sub>50</sub>s = 0.30 and 58 nM, respectively) shows good pharmacokinetics in rats, dogs, and
-
18129-10An orally bioavailable inhibitor of ACAT (IC<sub>50</sub>s = 24 and 9.2 µM for ACAT1 and ACAT2, respectively) that reduces plasma total triglyceride and VLDL cholesterol levels in cholesterol-fed animal models also used to decrease amyloid